An every-4-week combination for CLL. Expect lowered blood counts and, importantly, a lowered immune system for months — so you'll take preventive antibiotics/antivirals. Watch for fever/infection and, uncommonly, sudden anemia from an immune reaction. Your team screens for hepatitis B before the rituximab.
Fludarabine + cyclophosphamide + rituximab every 4 weeks. Blood-count drops are nadir-based (neutrophil nadir ~day 13, platelet ~day 16). A signature feature is PROLONGED immune suppression (fludarabine lowers immune T-cells for months → opportunistic infections; preventive antibiotics/antivirals are given). Small long-term risks include prolonged low counts and, rarely, a treatment-related blood cancer.
Get help straight away — this is true on any regimen, on any day.
A temperature of 100.4°F (38°C) or higher during treatment can mean a
serious infection while your blood counts are low. Call your team or go to the ER — do not
wait it out.
Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat ·
new confusion or fainting · shaking chills · not being able to keep fluids down.
This is standing guidance shown to everyone. Nothing on this page is based on anything
about you, and nobody is monitoring you.
3 of the 8 entries below are marked provisional.
They are shown because leaving them out would be its own distortion, but they have not yet
been checked against the source document by a person, and they are not presented as
authoritative. Every provisional entry is labelled where it appears.
Timed to the cycle
Day 1 is the day of your infusion. These are the effects a retrievable
document ties to a day range for this regimen — not a prediction about you.
Infusion reaction (rituximab)
During or just after an infusion
A reaction during the first rituximab infusion (chills, fever, flushing) — less likely later. You'll be pre-medicated and watched; the first cycle also carries a tumor-lysis risk that's prevented with fluids and medicine.
Call your team urgently: Any trouble breathing, throat tightness, or dizziness during the infusion — tell staff at once.
reported by about 59% of people; severe in 9% · Timing is part of what this effect is · from Rituximab
Neutropenia
Typically around days 8–20
A drop in infection-fighting white cells; the low point is usually around day 13. Your team checks counts before each cycle.
Call your team urgently: A temperature of 100.4°F (38.0°C) or higher — an emergency.
severe in 30-34% · Timing from the manufacturer’s prescribing information · from Fludarabine, Cyclophosphamide
Anemia and low platelets
Typically around days 8–20
Drops in red cells (tiredness, breathlessness) and platelets (bruising, bleeding), lowest in the middle of the cycle.
Call your team: New breathlessness, or bleeding that won't stop / black stools.
reported by about Hgb drop ≥2 g/dL ~60%; platelet drop ≥50% ~55%% of people · Timing from the manufacturer’s prescribing information · from Fludarabine, Cyclophosphamide
Not tied to a cycle day
These build with the number of doses, or are measured from when treatment started, so a cycle day would be the wrong shape for them. Each keeps the timing its own source states.
Prolonged immune suppression with infections
prolonged (months); slow immune recovery
Fludarabine lowers immune T-cells deeply and for months, raising the risk of unusual ('opportunistic') infections and reactivation of viruses (shingles, rarely a serious brain infection called PML). You'll take preventive antibiotics/antivirals — take them as directed and report any fever or new neurological symptoms.
Call your team urgently: Fever, breathlessness, or new confusion, weakness, or vision changes — contact your team.
reported by about 33-44% infections (opportunistic risk) of people · from Fludarabine
Autoimmune hemolytic anemiaPROVISIONAL
any time on treatment
Uncommonly, fludarabine can trigger the immune system to destroy red cells, causing sudden tiredness, breathlessness, or yellowing. It's treated with steroids and stopping the drug — and can recur if the drug is restarted, so report symptoms promptly.
Call your team urgently: Sudden breathlessness, dark urine, or yellowing of skin/eyes.
reported by about ~1-5% of people · from Fludarabine
Prolonged low counts (late)
persists/appears after treatment
In some people, blood counts stay low for a prolonged time after treatment (weeks to up to a year). Your team monitors counts well beyond the treatment cycles.
reported by about ~8.5% prolonged neutropenia of people · from Fludarabine
Later risk: therapy-related MDS/AMLPROVISIONAL
years after treatment
A small long-term risk of a treatment-related blood cancer (myelodysplasia/AML) years later. Your team keeps you under long-term monitoring.
reported by about ~2-5% (long-term) of people · from Fludarabine, Cyclophosphamide
NauseaPROVISIONAL
Sickness in the first 24 hours is the "acute" phase and usually peaks 2-3 hours in; anything from 24 to 120 hours is the "delayed" phase.
Usually mild-moderate and controlled with anti-nausea medicine.
reported by about ~30-40% of people · Timing from a clinical guideline · from Fludarabine, Cyclophosphamide
Where this comes from
S1. Hallek M, CLL8 (FC vs FCR, untreated CLL) + Rituxan label (CLL Study 1) (2010) — PMID 20888994
S2. Fludarabine phosphate FDA label (nadir timing; opportunistic infections; autoimmune hemolysis; prolonged cytopenias) — FDA label
S3. Rituximab (Rituxan) FDA label (infusion reactions; HBV reactivation; TLS) — FDA label
Timing windows on this page rest on:
Cyclophosphamide FDA prescribing information — “The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment ... normalize after approximately 20 days” source
Definitional — an infusion reaction is one that occurs during or shortly after the infusion — “The timing is part of what the term denotes; there is no empirical claim here to source.”
A window appears here only where a retrievable document ties it to a drug in
this regimen. Where nothing could be found, the window was removed rather than estimated —
so a missing time is an honest gap, not an oversight.